



# Glycogen Synthase Kinase3 Beta Phosphorylates Serine 33 of p53 and Activates p53's Transcriptional Activity

## Citation

Turenne, Gaetan A, and Brendan D Price. 2001. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. BMC Cell Biology 2: 12.

## Published Version

doi://10.1186/1471-2121-2-12

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:4791066>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

## Research article

# Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity

Gaetan A Turenne and Brendan D Price\*

Address: Department of Radiation Oncology, D810A, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, MA, 02115, USA

E-mail: Gaetan A Turenne - [ATurenne@kendallstrategies.com](mailto:ATurenne@kendallstrategies.com); Brendan D Price\* - [brendan\\_price@dfci.harvard.edu](mailto:brendan_price@dfci.harvard.edu)

\*Corresponding author

Published: 16 July 2001

Received: 13 April 2001

BMC Cell Biology 2001, 2:12

Accepted: 16 July 2001

This article is available from: <http://www.biomedcentral.com/1471-2121/2/12>

© 2001 Turenne and Price; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-commercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact [info@biomedcentral.com](mailto:info@biomedcentral.com)

## Abstract

**Background:** The p53 protein is activated by genotoxic stress, oncogene expression and during senescence, p53 transcriptionally activates genes involved in growth arrest and apoptosis. p53 activation is regulated by post-translational modification, including phosphorylation of the N-terminal transactivation domain. Here, we have examined how Glycogen Synthase Kinase (GSK3), a protein kinase involved in tumorigenesis, differentiation and apoptosis, phosphorylates and regulates p53.

**Results:** The 2 isoforms of GSK3, GSK3 $\alpha$  and GSK3 $\beta$ , phosphorylate the sequence Ser-X-X-Ser(P) when the C-terminal serine residue is already phosphorylated. Several p53 kinases were examined for their ability to create GSK3 phosphorylation sites on the p53 protein. Our results demonstrate that phosphorylation of serine 37 of p53 by DNA-PK creates a site for GSK3 $\beta$  phosphorylation at serine 33 *in vitro*. GSK3 $\alpha$  did not phosphorylate p53 under any condition. GSK3 $\beta$  increased the transcriptional activity of the p53 protein *in vivo*. Mutation of either serine 33 or serine 37 of p53 to alanine blocked the ability of GSK3 $\beta$  to regulate p53 transcriptional activity. GSK3 $\beta$  is therefore able to regulate p53 function *in vivo*. p53's transcriptional activity is commonly increased by DNA damage. However, GSK3 $\beta$  kinase activity was inhibited in response to DNA damage, suggesting that GSK3 $\beta$  regulation of p53 is not involved in the p53-DNA damage response.

**Conclusions:** GSK3 $\beta$  can regulate p53's transcriptional activity by phosphorylating serine 33. However, GSK3 $\beta$  does not appear to be part of the p53-DNA damage response pathway. Instead, GSK3 $\beta$  may provide the link between p53 and non-DNA damage mechanisms for p53 activation.

## Background

The p53 tumor suppressor gene is activated during several cellular processes. These include DNA damage caused by Ionizing Radiation and genotoxic agents [1], by expression of activated oncogenes such as ras or myc [2], or during progression of primary cells to senescence [3]. The activation of p53 by these diverse stimuli can in-

itiate either growth arrest or apoptosis depending on the cellular context [1,2,3]. p53 possesses sequence-specific DNA binding activity and functions in the cell as a transcriptional regulator. Many p53 regulated genes have been identified [3,4,5], and the majority of the cellular effects of p53 activation can be attributed to the activation of these p53 target genes.

The mechanism of p53 activation in response to either DNA damage or oncogene expression occurs through stabilization of the p53 protein. In unstimulated cells, the mdm2 protein binds to the N-terminal transactivation domain of p53 and targets it for ubiquitin-dependent degradation [6,7]. Activation of p53 requires disruption of the mdm2-p53 interaction to allow p53 accumulation in the cell. 2 distinct mechanisms for p53 activation have so far been elucidated. The expression of oncogenes such as ras in untransformed cells stimulates transcription of the p14<sup>Arf</sup> gene [2]. p14<sup>Arf</sup> binds to and sequesters mdm2, allowing free p53 protein to accumulate in the cells [8]. Activation of p53 by DNA damage is also brought about by inhibition of p53-mdm2 interaction. The product of the Ataxia Telangiectasia gene, the ATM protein kinase [9], directly phosphorylates serine 15 of the p53 protein in response to Ionizing Radiation [10,11]. In addition, ATM phosphorylates and activates chk2 kinase [12]. Activated chk2 can then directly phosphorylate serine 20 of p53 [13,14]. ATM therefore controls the phosphorylation of serines 15 and 20 of p53. In addition, DNA damage increases the phosphorylation of serines 33 and 37 of p53 through an ATM-independent mechanism [15,16,17,18]. These DNA damage-induced phosphorylations of p53 block the binding of mdm2 to the N-terminal of the p53 protein [18]. Thus phosphorylation of the p53 protein in response to DNA damage or expression of p14<sup>Arf</sup> prevents mdm2 binding and p53 protein then accumulates in the cell.

Although stabilization of the p53 protein is the initial step in p53 activation, subsequent steps, including activation of p53's DNA binding activity and changes in p53's transcriptional activity, are also involved. For example, p53's DNA binding activity is increased by the DNA damage-induced acetylation of the C-terminal of p53 [16,19], and this acetylation requires the prior phosphorylation of the N-terminal of p53 [16]. In addition, phosphorylation of the N-terminal transactivation domain of p53 may be required to stimulate transcriptional activation of p53 target genes. Multiple phosphorylation sites have been detected in the N-terminal of p53, including serines 6, 9, 15, 20, 33, 37 and 46 [10,11,12,13,14, 20,21,22]. While phosphorylation of serines 15 and 20 of p53 are clearly dependent on the ATM and chk2 protein kinases [10,11,12,13,14], the kinases responsible for phosphorylation of the remaining serine residues *in vivo* is not clear.

The activation of p53 by DNA damage or oncogenes such as ras results in either growth arrest or apoptosis of the affected cell. In this study, we have examined how Glycogen Synthase Kinase 3 $\beta$  (GSK3 $\beta$ ), a protein kinase involved in tumorigenesis, differentiation and apoptosis, regulates the function of p53 [23,24]. GSK3 $\beta$  phosphor-

ylates several transcription factors, including NFATc and HSF1 [24,25,26,27]. GSK3 $\beta$  is constitutively active in resting cells but is inhibited when cells are exposed to growth factors [24,28].


GSK3 inhibition occurs when the p110-PI 3-kinase/Protein Kinase B (PKB) pathway is activated by growth factors [23,24,25,29]. Activated PKB then phosphorylates GSK3 $\beta$ , inhibiting GSK3 kinase activity [29]. This activation of the p110-PI 3-kinase/PKB pathway, and inhibition of GSK3, delivers a strong anti-apoptotic signal to the cell [23,24,25]. Given the well characterized role of p53 in apoptosis [3,4,5], we examined if GSK3p participates in the regulation of the p53 protein.

GSK3 phosphorylates the consensus sequence Ser-X-X-X-Ser(P), where the C-terminal serine residue is already phosphorylated [24,28]. Thus GSK3 only phosphorylates target proteins which have already been phosphorylated by a separate, priming kinase. p53 contains 5 potential GSK3 phosphorylation sites, 3 in the N-terminal transactivation domain and 2 in the C-terminal regulatory domain. Here, we show that GSK3 $\beta$ , but not GSK3 $\alpha$ , can phosphorylate serine 33 of p53 *in vitro* when serine 37 is already phosphorylated. Further, GSK3 $\beta$  can increase p53's transcriptional activity *in vivo*, and this activation is lost when serine 33 is mutated to alanine.

## Results

The p53 protein contains several serine residues which are located within potential GSK3 phosphorylation sites. Protein kinases which can phosphorylate p53 within these predicted GSK3 sites include MAP kinase, Protein Kinase A, Protein Kinase C, Casein Kinase II, Jun kinase (JNK) and DNA-dependent Protein Kinase (DNA-PK) [30,31,32,33,34,35]. These kinases were examined to determine if they can act as the priming kinase for either of the 2 isoforms of GSK3, GSK3 $\alpha$  and GSK3 $\beta$ . The general protocol was to incubate purified priming kinases with p53-GST fusion protein and ATP for 5 h, then heat inactivate the priming kinase. Preliminary experiments indicated that each of the tested kinases was able to phosphorylate p53-GST under the experimental conditions (data not shown). Aliquots of the prephosphorylated p53-GST were then incubated with or without recombinant GSK3 $\alpha$  or GSK3 $\beta$  and <sup>32</sup>P-ATP to measure p53 phosphorylation.

p53-GST preincubated in buffer alone, and then exposed to the heat inactivation protocol was not phosphorylated by either GSK3 $\alpha$  or GSK3 $\beta$  (fig 1, Control). Autophosphorylation of GSK3 $\alpha$  and GSK3 $\beta$  can be seen (figure 1). Unphosphorylated p53-GST is therefore not a substrate for GSK3 $\alpha$  or GSK3 $\beta$  *in vitro*. p53-GST was then prephosphorylated with MAP kinase, S6 kinase, Protein Ki-

**Figure 1**

**Phosphorylation of p53 by GSK3β.** p53-GST (2 μg) was incubated in the absence (Control) or presence of the indicated protein kinase as described in methods. Primary kinases were then heat inactivated (65°C/15 min). Aliquots of the phosphorylated p53-GST were then incubated in the absence (-), or presence of recombinant GSK3α (α) or GSK3β (β) and 10 μCi <sup>32</sup>P-ATP. Phosphorylated p53-GST (0.25 μg total p53-GST) was detected by SDS-PAGE followed by auto-radiography. MAPK, MAP kinase; S6 Kin, S6 Kinase; PKA, Protein Kinase A; PKC, Protein Kinase C.


nase A, DNA-PK and Protein Kinase C (fig 1) or Casein Kinase II and JNK1/JNK2 (data not shown). Following incubation in each of the primary kinases, the prephosphorylated p53-GST was then incubated with <sup>32</sup>P-ATP and either GSK3α or GSK3β. Prephosphorylation of p53-GST by MAP kinase, S6 kinase, Protein Kinase A or Protein Kinase C (fig 1) or Casein Kinase II or JNK1 or JNK2 (data not shown) failed to create a phosphorylation site for either GSK3α or GSK3β. However, prephosphorylation of p53-GST by DNA-PK resulted in strong phosphorylation of p53 by GSK3β (fig 1) but not GSK3α. GST protein alone incubated with DNA-PK was not phosphorylated by GSK3β (data not shown). Since there was no significant phosphorylation of p53-GST by GSK3α (fig 1), this indicates that phosphorylation of p53 by DNA-PK, *in vitro*, creates a site for GSK3β to phosphorylate p53.

Next, we set out to identify the exact amino-acid(s) within the p53 protein which were phosphorylated by GSK3β. p53 is phosphorylated by DNA-PK at serines 15 and 37 [32]. Of these 2 sites, the sequence around serine 37 contains a predicted GSK3 phosphorylation site at serine 33 (figure 2, underlined). Serine 33 and 37 of p53 were individually mutated to alanine, and p53-GST fusion proteins containing these mutations prepared. The ability of DNA-PK to create a GSK3β phosphorylation site on these p53 proteins was then examined.

In the absence of p53, no phosphorylation by GSK3β was detected (fig 2). Unphosphorylated p53-GST was not a substrate for GSK3β, whereas p53-GST prephosphor-

ylated by DNA-PK was (fig 2). Mutation of serine 33 of p53 to alanine (S33A) blocked the ability of GSK3β to phosphorylate p53, indicating that serine 33 is the likely target for GSK3β (fig 2, 33). Similarly, mutation of serine 37, which abolishes the DNA-PK phosphorylation site, blocks phosphorylation of p53 by GSK3β. This indicates that p53 must be phosphorylated on serine 37 by DNA-PK before it can be phosphorylated at serine 33 by GSK3β.


To examine the *in vivo* function of these *in vitro* phosphorylations, wtp53 and p53 with the S33A and S37A mutations were sub-cloned into the expression vector pcDNA3.1. These were then expressed in the human osteosarcoma cell line SAOS-2, which does not express endogenous p53 protein [33]. First, we analyzed the level of expression of each of the p53 proteins following transient expression in SAOS-2 cells. In fig 3A, approx equal amounts of wtp53, p53S33A and p53S37A were detected by western blot, indicating that they were expressed at similar levels. In fig 3B, we examined the transcriptional activity of these p53 constructs. A p53-reporter construct, p50-2, which specifically responds to wtp53 by increasing transcription of the luciferase gene, was used [described in 33]. In fig 3B, SAOS-2 cells transiently expressing vector (Con), showed minimal activation of the p53-reporter construct. Cells expressing wtp53 showed significant activation, as did cells expressing both the S33A and S37A mutations. Both the S33A and S37A mutations displayed slightly higher basal levels of transcriptional activity than the wtp53 protein.

**Figure 2**

**GSK3 $\beta$  phosphorylates serine 33 of p53.** wtp53-GST (W), p53-GSTS33A (33) or p53-GSTS37A (37) were preincubated in buffer (-) or DNA-PK (+) for 5 h in the presence of excess ATP. Following heat inactivation of the DNA-PK, aliquots of the phosphorylated p53-GST fusion proteins were incubated for 30 min without (-) or with (+) GSK-3 $\beta$ . Position of p53-GST and GSK3 $\beta$  is indicated. The sequence of p53 around serines 15 and 37 is shown below the figure.

Serines 33 and 37 are located within the N-terminal transcriptional activation domain of the p53 protein. To determine if GSK3 $\beta$  regulates p53's transcriptional activity *in vivo*, a wild type GSK3 $\beta$  expression vector was cotransfected with either wtp53 or p53 with mutations in serines 33 or 37. The ability of GSK3 $\beta$  to activate each construct was calculated by expressing the p53 transcriptional activity in the presence of GSK3 $\beta$  as a percentage of that observed in the absence of GSK3 $\beta$ . On this scale, no activation by GSK3 $\beta$  yields a zero percent increase in p53 transcriptional relative to p53 alone. GSK3 $\beta$  alone (fig 3C, Con) did not significantly increase the activity of the luciferase reporter construct. When GSK3 $\beta$  was cotransfected with wtp53, p53-dependent activity from the luciferase reporter construct was increased by 160% compared to wtp53 alone. To determine

if this activation of p53 transcriptional activity required the GSK3 $\beta$  phosphorylation site at serine 33, wtp53 with serine to alanine mutations at either positions 33 or 37 were cotransfected with GSK3 $\beta$ . Mutation of either serine 33 or 37 significantly reduced the ability of GSK3 $\beta$  to upregulate p53 transcriptional activity. This is consistent with the phosphorylation data in fig 1 and 2, which indicated that serine 37 phosphorylation is required for the subsequent phosphorylation of serine 33 by GSK3 $\beta$ . These results suggests that GSK3 $\beta$  may be a physiological regulator of the p53 protein. GSK3 $\beta$  is constitutively active in resting cells, and is inactivated by PKB through the growth factor dependent p110-PI 3-kinase pathway [25,28,29]. Thus the activity of GSK3 $\beta$  in growing cells is less than that in cells arrested in G<sub>0</sub>. p53 can be activated by several distinct pathways, including DNA damage. If

**Figure 3**


**GSK3 $\beta$  regulates p53 transcriptional activity.** (A) SAOS-2 cells were transiently transfected with vector (pcDNA3.1), or expression vectors for wtp53, wtp53S33A (S33A) or wtp53S37A (S37A). p53 expression was detected by western blotting. (B+C). SAOS-2 cells were transiently transfected with p50-2, a p53-responsive luciferase reporter construct, and 50 ng of vector (Con), wtp53, wtp53S33A (S33A), or wtp53S37A (S37A) as indicated,  $\beta$ -galactosidase activity from pCMV-Gal was used to adjust for transfection efficiency. In (B), the actual transcriptional activity of each p53 construct is shown. In (C), cells were cotransfected with an expression vector for GSK3 $\beta$  (pcDGSKS $\beta$ ; 800 ng). The transcriptional activity was calculated by dividing p53 activity in the presence of GSK3 $\beta$  by p53 activity in the absence of GSK3 $\beta$  and expressing the answer as a percentage. 0% = no increase

GSK3 $\beta$  is involved in the activation of p53 by DNA damage, then GSK3 $\beta$  is predicted to be upregulated in response to DNA damage. In fig 4, GSK3 $\beta$  kinase activity was monitored by immunoprecipitating GSK3 $\beta$  and then measuring the ability of the immunoprecipitated protein to phosphorylate a specific GSK3 $\beta$  peptide substrate. In fig 4, the omission of either the peptide or the GSK3 $\beta$  antibody from the assay resulted in minimal phosphorylation of the substrate peptide (fig 4). When both GSK3 $\beta$  antibody and substrate peptide were employed, high levels of GSK3 $\beta$ -dependent kinase activity were detected. When cells were incubated for 24 h in low serum (0.5%) to induce growth arrest in G<sub>0</sub>, the levels of GSK3 $\beta$  activity were increased compared to asynchronously growing cells (fig 4, G<sub>0</sub>). When asynchronously growing cells were exposed to 5Gy or 10Gy of Ionizing Radiation to cause DNA damage, the levels of GSK3 $\beta$  activity were reduced. Similar results were seen using p53-GST as the substrate for GSK3 $\beta$  phosphorylation in the kinase assay (data not shown). This implies that the phosphorylation of serine 33 of p53 by GSK3 $\beta$  would be decreased in cells exposed to DNA damage, but elevated in cells growth arrested in G<sub>0</sub>.

## Discussion

Several p53 kinases were examined for their ability to create *in vitro* GSK3 phosphorylation sites on p53. Phosphorylation of p53 by DNA-PK created a phosphorylation site for GSK3 $\beta$ , but not for GSK3 $\alpha$ . GSK3 $\alpha$  and GSK3 $\beta$  have 98% homology within the kinase domain, although regions N- and C-terminal to this are less well conserved [36]. GSK3 $\alpha$  and GSK3 $\beta$  have similar substrate specificity *in vivo*, and are regulated in parallel in response to growth factors [24,27,28,29]. However, disruption of GSK3 $\beta$  in mice results in embryonic lethality and impaired NF $\kappa$ B function [37], indicating that GSK3 $\alpha$  cannot substitute for GSK3 $\beta$  in this model system. GSK3 $\alpha$  and GSK3 $\beta$  therefore have overlapping cellular functions, but each isoform also regulates distinct signaling pathways. Our results clearly show that p53 phosphorylation is specific for GSK3 $\beta$ .

The GSK3 $\beta$  phosphorylation site was identified by mutagenesis as serine 33 of p53, and we were able to show that this was dependent on prior phosphorylation of serine 37 by DNA-PK. We also examined if GSK3 $\beta$  regulates *in vivo* p53 function through a mechanism involving serines 33 and 37 of p53. Previous studies have shown that phosphorylation of serines 15, 20, 33 and 37 of p53 block



**Figure 4**  
**Ionizing Radiation inhibits GSK3 $\beta$  kinase activity.** SAOS-2 cells were immunoprecipitated with anti-GSK3 antibody and incubated with CREB phosphopeptide substrate. Total CPM incorporated into the substrate peptide are shown. **Pep:** Assays carried out with or without peptide. **Ab:** Immunoprecipitation carried out with either IgG or anti-GSK3 antibody (+). **Cell:** Cells were either growing asynchronously (+) or preincubated for 24 h in 0.5% Serum to induce quiescence (Go). **IR:** Cells were exposed to 5 or 10Gy of Ionizing Radiation and allowed to recover for 60 min.

the interaction of p53 with mdm2, leading to stabilization and accumulation of p53 protein in the cell [10,11,13,14,15,18]. mdm2 binding is dependent on the phosphorylation status of serine 20 of p53 [15], although phosphorylation of serines 15, 33 and 37 also play a role. We did not detect any significant difference in the level of expression of p53 with single mutations in either serines 33 or 37 when compared to wtp53, indicating that single

point mutations in serines 33 or 37 do not greatly alter p53 stability.

A key function of p53 is the transcriptional activation of genes which regulate growth arrest and apoptosis [1,2,3,4]. Individual mutation of either serine 33 or 37 slightly increased the basal transcriptional activity of the p53 protein. This is in keeping with observations made by other groups, who demonstrated that single or multi-



ple mutations in p53 phosphorylation sites has minimal effect on the basal transcriptional activity of the p53 protein [38,39,40]. We also determined if GSK3 $\beta$  could regulate p53 transcriptional activity *in vivo*. GSK3 $\beta$  is constitutively active in resting cells, but exhibits lower activity in asynchronously growing cells [24]. To increase the activity of GSK3 $\beta$ , we co-transfected GSK3 $\beta$  with either wtp53 or p53 bearing serine to alanine mutations at positions 33 or 37. GSK3 $\beta$  increased the transcriptional activity of wtp53, but not of p53 with mutations in either serine 33 or 37. Therefore both serine 33 and serine 37 are required for GSK3 $\beta$  to activate p53 transcriptional activity *in vivo*. GSK3 $\beta$  regulates many stress activated transcription factors. For example, GSK3 $\beta$  is required for activation of NF $\kappa$ B [37], but inhibits activation of Heat Shock Factor-1 [27]. Our results indicate that GSK3 $\beta$  may also be involved in the activation of the p53 protein as well.

A key question is whether DNA-PK or some other kinase phosphorylates serine 37 of p53 *in vivo*. DNA-PK is 460 kD DNA-activated protein kinase which participates in the cellular response to DNA damage [41]. DNA-PK is involved in DNA strand-break repair, and can phosphorylate serines 15 and serine 37 of p53 *in vitro* [32]. Some reports indicate that DNA-PK is required for the activation of p53 [42], but recent genetic studies have shown clearly that DNA-PK is not required for p53 activation by Ionizing Radiation [43]. Whether DNA-PK is required for p53 activation in response to other stimuli is not known. A more likely candidate is the Atr protein kinase, a kinase related to DNA-PK [44], which can regulate the phosphorylation of serine 37 of p53 in response to DNA damage. The present data indicates that transcriptional activation of p53 by GSK3 $\beta$  requires both serines 33 and 37, but it does not allow us to determine if phosphorylation of serine 33 is dependent on phosphorylation of serine 37 *in vivo*. It is possible that, *in vivo*, GSK3 $\beta$  directly phosphorylates serine 33 independently of serine 37, but that both residues must be phosphorylated for transcriptional activation to occur *in vivo*. Future studies will address this issue.

p53 is activated by multiple pathways, including DNA damage and oncogene activation [1,2,3]. If GSK3 $\beta$  is required for the activation of p53 by DNA damage, GSK3 $\beta$  activity should be regulated by DNA damage. However, when cells were exposed to Ionizing Radiation, GSK3 $\beta$  kinase activity was inhibited rather than enhanced, implying decreased GSK3 $\beta$ -dependent phosphorylation of p53 after DNA damage. Serine 33 of p53 is also phosphorylated by other kinases, including the CDK7-cyclin H complex [45] and p38 MAPK [46]. p38 MAPK is involved in p53 activation by genotoxic stress [46], and may be responsible for p53 phosphorylation at serine 33 in

response to DNA damage. GSK3 $\beta$ -dependent phosphorylation of p53 at serine 33 may be part of other p53-regulatory pathways, such as oncogene activation or apoptosis, which are not directly activated by DNA-damage. For example, activation of the p110-PI 3-kinase/PKB pathway delivers an anti-apoptotic signal to the cell [23,25,47]. Further, activation of the p110-PI 3-kinase/PKB is associated with inhibition of both p53 dependent apoptosis [48] and p53 transcriptional activity [49,50]. Although PKB has many downstream targets which may regulate these effects [47] a key target of PKB is GSK3 $\beta$  [29]. Phosphorylation of GSK3 $\beta$  by PKB inhibits GSK3 $\beta$  kinase activity [29]. This would be predicted to block phosphorylation of serine 33 of p53 by GSK3 $\beta$ , decreasing p53 transcriptional activity and therefore reducing the transcription of p53-regulated growth and pro-apoptotic proteins. However, clarification of the potential role of GSK3 $\beta$  in regulating p53 activation by non-DNA damage pathways will require additional study.

## Conclusions

This study demonstrates that GSK3 $\beta$ , but not GSK3 $\alpha$ , can directly phosphorylate serine 33 of p53 when serine 37 of p53 is already phosphorylated. GSK3 $\beta$  can increase p53's transcriptional activity *in vivo*, and this activation requires serines 33 and 37 of the p53 protein. Thus GSK3 $\beta$  may phosphorylate and activate p53 *in vivo*. However, GSK3 $\beta$  is not part of the p53-DNA damage response pathway. Instead, GSK3 $\beta$  may provide the link between p53 and non-DNA damage mechanisms for p53 activation, such as oncogene activation.

## Materials and methods

### Phosphorylation Reactions

Wild type p53 or p53 bearing mutations in serines 33 or 37 were subcloned into pGEX-2T GST fusion vector (Pharmacia, NJ) and p53-GST purified as previously described [33]. p53-GST protein (2  $\mu$ g; measured using Bio-Rad Protein assay Kit, Biorad, CA) was incubated with MAP kinase (Erk2, 10 Units, New England Biolabs, MA), Protein Kinase A (Catalytic sub-unit, 5 Units, Calbiochem, CA), S6 kinase (0.2 Units, Upstate Biotechnology, NY), Protein Kinase C (0.1 mUnits, Roche Molecular Biochemicals, IN) or DNA-PK (20 Units, Promega Corp, WI) for 5 h at 30°C in the following buffers (40  $\mu$ l final volume). MAP kinase and Protein Kinase A: 20 mM Hepes pH 7.2/10 mM Na-Acetate/30 mM MgCl<sub>2</sub>/0.2 mM EDTA/1 mM EDTA/10  $\mu$ M ATP. S6 Kinase: 20 mM MOPS pH 7.2/30 mM MgCl<sub>2</sub>/5 mM EGTA/1 mM DTT/10  $\mu$ M ATP. DNA-PK: 25 mM Hepes pH 7.5/150 mM KCl/10 mM MgCl<sub>2</sub>/20% Glycerol/0.1% NP40/20  $\mu$ M ZnCl<sub>2</sub>/1 mM DTT/250 ng DNA/4.2 mM spermidine/10  $\mu$ M ATP. PKC: 20 mM Hepes pH 7.4/20 mM MgCl<sub>2</sub>/0.2 mM EGTA/1 mM CaCl<sub>2</sub>/1.5  $\mu$ g phosphatidylserine. Samples were then incubated at 65°C for 20



min to inactivate kinases, and 25% of the reaction incubated for 30 min with GSK3 $\alpha$  or GSK3 $\beta$  in GSK3 kinase buffer (KGB Buffer: 8 mM MOPS, pH7.2/ 10 mM MgCl<sub>2</sub>/ 0.2 mM EDTA/ 5  $\mu$ M ATP/10  $\mu$ Ci 32P-ATP) in a final volume of 40  $\mu$ l. Reactions were terminated by the addition of SDS sample buffer and p53-GST phosphorylation detected by SDS-PAGE and autoradiography. Equal amounts of p53-GST (0.25  $\mu$ g) were analyzed by SDS-PAGE and equal loading confirmed by coomassie blue staining of the SDS-PAGE.

#### GSK3 immunokinase assay

SAOS-2 cells ( $5 \times 10^6$ ) were lysed in 0.5 ml of GLB buffer (50 mM Tris pH7.5/1 mM EDTA/1 mM EGTA/0.5% NP40/0.5 M NaCl/1 mM DTT/1 mM PMSF/leupeptin/aprotinin/600  $\mu$ M Na<sub>3</sub>VO<sub>4</sub>/50 mM NaF). Extracts were cleared by centrifugation and incubated with GSK3 antibody (1  $\mu$ g; Upstate Biotech, NY) prebound to Sepharose A/G agarose beads for 2 h. The beads were washed in  $4 \times 1$  ml of GLB buffer and then in  $2 \times 1$  ml of KGB buffer. Kinase reactions contained 5  $\mu$ M ATP/15  $\mu$ Ci <sup>32</sup>P-ATP/0.5  $\mu$ g PhosphoCREB peptide in 30  $\mu$ l of KGB. After incubate for 10 min at room temperature, the beads were collected by centrifugation and 20  $\mu$ l of the reaction mix spotted onto circles of P81 paper (Whatman, USA). The P81 paper was washed in  $4 \times 10$  ml changes of 100 mM phosphoric acid, dried and counted. PhosphoCREB peptide (sequence KRREILSRP(S)YR) was obtained from New England Biolabs, MA.

**Mutagenesis** was carried out using the Altered Sites Mutagenesis System (Promega, WI) as previously described by us [33]. Human wild type p53 or p53 bearing mutations in serines 33 or 37 were inserted into the BamH1 site of the pcDNA3.1 expression vector (Invitrogen, CA).

**Luciferase reporter assays** were carried out in the p53 null cell line SAOS-2 using the p53 specific luciferase reporter construct p50-Luc, and pCMV- $\beta$ -galactosidase to control for transfection efficiency. Cells were transfected using Lipofectin (Gibco-BRL) containing p50-Luc (1  $\mu$ g), pCMV-Gal (1  $\mu$ g) and pcDNAp53 (50 ng) in a final volume of 400  $\mu$ l as described in the manufacturers protocol.

#### Acknowledgements

We thank J. Woodgett for GSK3 $\beta$  cDNA. This work was supported by grant number CA64585 to BDP and funds from the AJCRT foundation.

#### References

- Canman CE, Lim D-S: **The role of ATM in DNA damage responses to cancer** *Oncogene* 1998, **17**:3301-3308
- Lowe SW: **Activation of p53 by Oncogenes** *Endocr Relat* 1999, **6**:45-48
- Lundberg AS, Hahn WC, Gupta P, Weinberg RA: **Genes involved in senescence and immortalization** *Curr Opin Cell Biol.* 2000, **12**:705-709
- Vousden KH: **p53:death star** *Cell* 2000, **103**:691-694
- Vogelstein B, Lane D, Levine AJ: **Surfing the p53 network** *Nature* 2001, **108**:307-310
- Haupt Y, Maya R, Kazaz A, Oren M: **Mdm2 promotes the rapid degradation of p53** *Nature* 1997, **387**:296-299
- Kubbutat MCG, Jones SN, Vousden KH: **Regulation of p53 stability by mdm2** *Nature* 1997, **387**:299-303
- Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlov I, Lee H-W, Cordon-Cardo C, De-Pinho RA: **The Ink4a tumor suppressor gene product p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53** *Cell* 1998, **92**:713-723
- Meyn MS: **Ataxia Telangiectasia, cancer and the pathobiology of the ATM gene** *Clin Genet* 1999, **55**:289-304
- Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y: **Enhanced phosphorylation of p53 by ATM in response to DNA damage** *Science* 1998, **281**:1674-1678
- Canman CE, Lim D-S, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD: **Activation of the ATM kinase by ionizing radiation and phosphorylation of p53** *Science* 1998, **281**:1677-1682
- Matsuoka S, Huang M, Elledge SJ: **Linkage of ATM to cell cycle regulation by the chk2 protein kinase** *Science* 1998, **282**:1893-1897
- Shieh S-Y, Ahn J, Tamai K, Taya Y, Prives C: **The human homologs of checkpoint kinases Chk1 and Cds1 (chk2) phosphorylate p53 at multiple DNA damage-inducible sites** *Genes Dev* 2000, **14**:289-300
- Chebub NH, Malikzay A, Appel M, Halazonetis TD: **Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53** *Genes Dev* 2000, **14**:278-288
- Shieh S-Y, Taya Y, Prives C: **DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization** *EMBO J.* 1999, **18**:1815-1823
- Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E: **DNA damage activates p53 through a phosphorylation-acetylation cascade** *Genes Dev.* 1998, **12**:2831-2841
- Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB: **DNA damage induces phosphorylation of the amino-terminus of p53** *Genes Dev.* 1997, **11**:3471-3481
- Shieh S-Y, Ikeda M, Taya Y, Prives C: **DNA-damage induced phosphorylation of p53 alleviates inhibition by mdm2** *Cell* 1997, **91**:325-334
- Gu W, Roeder RG: **Activation of p53-sequence-specific DNA binding by acetylation of the p53 C-terminal domain** *Cell* 1997, **90**:595-606
- Steeenga WT, van der Eb AJ, Jochemsen AG: **How phosphorylation regulates the activity of p53** *J.Mol. Biol.* 1996, **263**:103-113
- Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y: **p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53** *Cell* 2000, **102**:849-862
- Higashimoto H, Saito S, Tong XH, Hong A, Sakaguchi K, Appella E, Anderson CW: **Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents** *J Biol Chem* 2000, **275**:23199-23203
- Franke TF, Kaplan DR, Cantley LC: **PI3K: Downstream Aktion blocks apoptosis** *Cell* 1997, **88**:435-437
- Kirn L, Kimmell AR: **GSK3, a master switch regulating cell-fate specification and tumorigenesis** *Curr Opin Gen Dev* 2000, **10**:508-514
- Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N: **The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal** *Genes Dev* 1997, **11**:701-713
- Neal JW, Clipstone NA: **Glycogen Synthase kinase-3 inhibits the DNA binding activity of NFATc** *J Biol Chem* 2000, **276**:3666-3673
- Xavier LJ, Mercier PA, McLoughlin CM, Ali A, Woodgett JR, Ovsenek N: **Glycogen Synthase Kinase 3 $\beta$  negatively regulates both DNA-Binding and transcriptional activities of Heat Shock factor-1** *J Biol Chem* 2000, **275**:29147-29152
- Eldar-Finkelman H, Argast GM, Foord B, EH Fischer, EG Krebs: **Expression and characterization of glycogen synthase kinase-3**

- mutants and their effect on glycogen synthase activity in intact cells** *Proc Natl Acad* 1996, **93**:1028-10233
29. Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: **Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B** *Nature* 1995, **378**:785-789
  30. Meek DW, Simon S, Kikkawa U, W Eckhart: **The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kinase II** *EMBO J* 1994, **9**:3253-3260
  31. Miller DM, Campbell DG, Caudwell FB, Meek DW: **Phosphorylation of the tumor suppressor p53 by mitogen activated kinases** *J Biol Chem* 1994, **269**:9253-9260
  32. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW: **Human DNA activated protein kinase phosphorylates serines 15 and 37 in the amino terminal transactivation domain of human p53** *Mol Cell Biol* 1992, **12**:5041-5049
  33. Youmell M, Park SJ, Basu S, Price BD: **Regulation of the p53 protein by protein kinase C $\alpha$  and protein kinase C $\epsilon$**  *Biochem Biophys Res Comm* 1998, **245**:514-518
  34. Adler V, Pincus MR, Minamoto T, Fuchs SY, Bluth MJ, Brandt-Rauf T, Friedman FK, Robison RC, Chen JM, Wang XW, Harris CC, Ronai Z: **Conformation-dependent phosphorylation of p53** *Proc Natl Acad Sci* 1997, **94**:1686-1691
  35. Fuchs SY, Adler V, Buschman T, Yin Z, Wu X, Jones SN, Ronai Z: **JNK targets p53 ubiquitination and degradation in nonstressed cells** *Genes Dev* 1998, **12**:2658-2663
  36. Woodgett JR: **Molecular cloning and expression of glycogen synthase kinase-3/Factor A** *EMBO J* 1990, **9**:2431-2438
  37. Hoeflich KP, Luo J, Ruble EA, Tsao M-S, Jin U, JR Woodgett: **Requirement for glycogen synthase kinase-3 $\beta$  in cell survival and NF- $\kappa$ B activation** *Nature* 2000, **406**:86-90
  38. Unger T, Sionov RV, Moallen E, Yee CL, Howley PM, Oren M, Haupt Y: **Mutations in serines 15 and 20 of human p53 impair its apoptotic activity** *Oncogene* 1999, **18**:3205-3212
  39. Ashcroft M, Kubbutata HG, Vousden KH: **Regulation of p53 function and stability by phosphorylation** *Mol. Cell Biol.* 1999, **19**:1751-1758
  40. Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ, Herrlich P: **DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation** *Oncogene* 1999, **18**:1723-1732
  41. Featherstone C, Jackson SP: **DNA-dependent protein kinase gets a break: its role in repairing DNA and maintaining genomic integrity** *Br J Cancer* 1999, **80 Suppl(1)**:14-19
  42. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PW: **DNA-dependent protein kinase acts upstream of p53 in response to DNA damage** *Nature* 1998, **394**:700-704
  43. Jimenez GS, Bryntesson F, Torres-Arzuayus MI, Priestly A, Beche M, Sakaguchi K, Appella E, Jeggo PA, Taccioli GE, Wahl GM, Hubank F: **DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage** *Nature* 1999, **400**:81-83
  44. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh S-Y, Taya Y, Prives C, Abraham RT: **A role for ATR in the DNA damage-induced phosphorylation of p53** *Genes Dev* 1999, **13**:152-157
  45. Jayaraman L, Tamai K, Taya Y, Prives C, ZQ Pan: **p53 is phosphorylated by CDK7-cyclin H in a p36mat1 dependent manner** *Mol Cell Biol* 1997, **17**:7220-7229
  46. Sanchez-Prieto R, Rojas JM, Taya Y, Gutkind JS: **A role for p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents** *Cancer Research* 2000, **60**:2464-2472
  47. Datta SR, Brunet A, Greenberg ME: **Cellular survival: a play in three acts** *Genes Dev* 1999, **13**:2905-2927
  48. Mazzoni IE, Said FA, Aloyz R, Miller FD, Kaplan D: **Ras regulates sympathetic neuron survival by suppressing the p53-mediated cell death pathway** *J Neuro* 1999, **19**:9716-9727
  49. Sabbatini P, McCormick F: **Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis** *J Biol Chem* 1999, **274**:24263-24269
  50. Yamaguchi A, Tamatani M, Matsuzuki H, Namikawa K, Kiyama H, Vitek MP, Mitsuda N, Tohyama M: **Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53** *J Biol Chem* 2001, **276**:5256-5264

Publish with **BioMedcentral** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright



Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>

[editorial@biomedcentral.com](mailto:editorial@biomedcentral.com)